For type 2 diabetes mellitus. ANDA 211052, held by Yichang Humanwell. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 211052 (Metformin Hydrochloride), held by Yichang Humanwell, was first approved by FDA on Sep 24, 2018, with 1 approved supplement and 0 published complete response letters.
Metformin Hydrochloride Extended-Release Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2018 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 24, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters